Halda Therapeutics

Halda is a biotechnology company focused on developing a new class of precision medicines known as RIPTAC therapeutics to combat cancer. These innovative drugs work by holding two proteins together: one that is tumor-specific and another that performs an essential function, resulting in the selective killing of cancer cells. Halda operates in the biotechnology and pharmaceutical market, primarily serving patients and healthcare providers in the oncology sector. The company's business model revolves around the research, development, and commercialization of these novel therapeutics. Revenue is generated through the sale of these drugs, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. Halda's leadership team, including CFO Scott Phillips, brings extensive experience in finance and biotech, ensuring robust financial management and strategic growth.

Keywords: RIPTAC therapeutics, precision medicine, cancer treatment, biotechnology, oncology, protein interaction, tumor-specific, drug development, healthcare, pharmaceutical.